|
WO2020198567A1
|
|
Quinoline derivatives and their use for the treatment of cancer
|
|
WO2020112872A1
|
|
Methods of treating whsc1-overexpressing cancers by inhibiting setd2
|
|
AU2019321464A1
|
|
Substituted indoles and methods of use thereof
|
|
AU2019309373A1
|
|
Pyridin-2-one compounds useful as SMARCA2 antagonists
|
|
EP3716964A1
|
|
Myst family histone acetyltransferase inhibitors
|
|
US2020123142A1
|
|
Substituted Cyclohexylamine Compounds
|
|
EP3697400A1
|
|
Methods of using ehmt2 inhibitors in treating or preventing blood disorders
|
|
EP3697420A1
|
|
Methods of using ehmt2 inhibitors in immunotherapies
|
|
WO2019079540A1
|
|
Amine-substituted heterocyclic compounds as ehmt2 inhibitors, salts thereof, and methods of synthesis thereof
|
|
CN111343988A
|
|
Amine-substituted heterocyclic compounds and derivatives thereof as EHMT2 inhibitors
|
|
CA3074720A1
|
|
Combination therapy for treating cancer
|
|
US2021002645A1
|
|
Methods Of Treating Cancer By Inhibiting SETD2
|
|
WO2018231973A1
|
|
Inhibitors of ezh2 and methods of use thereof
|
|
EP3630080A1
|
|
Use of ezh2 inhibitors for treating cancer
|
|
AU2018254577A1
|
|
Combination therapies with EHMT2 inhibitors
|
|
AU2018243749A1
|
|
Methods of using EHMT2 inhibitors
|
|
US2021100810A1
|
|
Combination therapy for treating cancer
|
|
SG11201907420VA
|
|
Inhibition of smarca2 for treatment of cancer
|
|
AU2018217139A1
|
|
Cancer treatment modalities
|
|
AU2017382830A1
|
|
Amine-substituted heterocyclic compounds as EHMT2 inhibitors and methods of use thereof
|
